#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)May 27, 2020

 

We are boldly reimagining cancer and blood disorders.

 

 

## Press releases

- [Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms](/news/media-releases/novartis-data-asco-and-eha-showcase-bold-approaches-reimagine-cancer-and-blood-disorders-through-multiple-therapeutic-platforms "Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms")
- [Novartis presents five-year analysis showing long-term data of targeted therapy in patients with high-risk, Stage III BRAF+ melanoma following surgery](/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery "Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery")
- [Novartis announces a subgroup analysis of overall survival results for our CDK4/6 inhibitor to be presented at ASCO20 Virtual Scientific Program](/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease "Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease")

---

## Now is the time to accelerate progress in cancer care

COVID-19 is having a huge impact on cancer care. Susanne Schaffert, President of Novartis Oncology, reflects on the current situation and looks at what can be done in this LinkedIn article.

[Read more](https://www.linkedin.com/pulse/now-time-accelerate-progress-cancer-care-susanne-schaffert-phd/)

---

## Additional resources

[ASCO20 Homepage](https://conferences.asco.org/am/attend)

---